A multicentre, open-label phase II study of I rinotecan, capecitabine ( X eloda ®), and O xaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Conclusion mIXO demonstrates promising ORR, PFS, OS, and acceptable toxicity compared to standard triplet regimens. IXO should be evaluated in phase III trials.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research